Pomalidomide Active Not Recruiting Phase 1 / 2 Trials for Multiple Myeloma (MM) Treatment

IndicationsStatusPurposePhase
Active Not RecruitingTreatment1 / 2
clinicaltrials.gov IdentifierTitleDrugs
NCT01998971A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
NCT02400242Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma
NCT02431208A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
NCT01562405Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT02616640A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma